Evidence for an effect of antithyroid drugs on the natural history of Graves' disease.
In the United Kingdom, about half the patients with Graves' disease who are given antithyroid drugs are still in remission one year after treatment is stopped. The most widely held view is that such remission rates are due only to the biochemical effects of the drugs, the disease either spontaneously remitting or abating when the immune system is no longer subject to the stimulatory effects of excessive thyroid hormone. We review here the accumulating evidence against both of these alternatives. In contrast, there is now a large body of work which shows that thyrotrophin receptor antibody levels, central to the aetiology of Graves' hyperthyroidism, fall during antithyroid treatment and that remission may be related to this fall in a fashion which is dependent on the dose and duration of treatment. This immunosuppressive effect is supported by experimental data and on the basis of these results we propose that antithyroid drugs may modify the natural history of Graves' disease and contribute to the remission which occurs in a proportion of treated patients.
D013956:Antithyroid Agents / Q000276:immunology / Q000627:therapeutic use*; D001323:Autoantibodies / Q000096:biosynthesis; D005260:Female; D006111:Graves Disease / Q000188:drug therapy*; D006801:Humans; D006980:Hyperthyroidism / Q000276:immunology; D007165:Immunosuppression Therapy; D008297:Male; D008713:Methimazole / Q000276:immunology; D011433:Propranolol / Q000627:therapeutic use; D012075:Remission, Spontaneous
D013956:Antithyroid Agents; D001323:Autoantibodies; D008713:Methimazole; D011433:Propranolol